scholarly journals Taking in the trash: bioreactors for the mass production of clinical-grade extracellular vesicles

Author(s):  
Matthew J. Robeson ◽  
Michael E. Davis
2021 ◽  
Vol 12 ◽  
pp. 204173142110190
Author(s):  
Jung-Hwan Lee ◽  
Ji-Young Yoon ◽  
Jun Hee Lee ◽  
Hae-Hyoung Lee ◽  
Jonathan C Knowles ◽  
...  

Extracellular vesicles (EVs), including exosomes, carry the genetic packages of RNA, DNA, and proteins and are heavily involved in cell-cell communications and intracellular signalings. Therefore, EVs are spotlighted as therapeutic mediators for the treatment of injured and dysfunctional tissues as well as biomarkers for the detection of disease status and progress. Several key issues in EVs, including payload content and bioactivity, targeting and bio-imaging ability, and mass-production, need to be improved to enable effective therapeutics and clinical translation. For this, significant efforts have been made recently, including genetic modification, biomolecular and chemical treatment, application of physical/mechanical cues, and 3D cultures. Here we communicate those recent technological advances made mainly in the biogenesis process of EVs or at post-collection stages, which ultimately aimed to improve the therapeutic efficacy in tissue healing and disease curing and the possibility of clinical translation. This communication will help tissue engineers and biomaterial scientists design and produce EVs optimally for tissue regenerative therapeutics.


Cells ◽  
2022 ◽  
Vol 11 (2) ◽  
pp. 186
Author(s):  
Asma Akbar ◽  
Farzaneh Malekian ◽  
Neda Baghban ◽  
Sai Priyanka Kodam ◽  
Mujib Ullah

The use of extracellular vesicles (EV) in nano drug delivery has been demonstrated in many previous studies. In this study, we discuss the sources of extracellular vesicles, including plant, salivary and urinary sources which are easily available but less sought after compared with blood and tissue. Extensive research in the past decade has established that the breadth of EV applications is wide. However, the efforts on standardizing the isolation and purification methods have not brought us to a point that can match the potential of extracellular vesicles for clinical use. The standardization can open doors for many researchers and clinicians alike to experiment with the proposed clinical uses with lesser concerns regarding untraceable side effects. It can make it easier to identify the mechanism of therapeutic benefits and to track the mechanism of any unforeseen effects observed.


2019 ◽  
Vol 316 (1) ◽  
pp. L6-L19 ◽  
Author(s):  
Andrea Porzionato ◽  
Patrizia Zaramella ◽  
Arben Dedja ◽  
Diego Guidolin ◽  
Kelly Van Wemmel ◽  
...  

Mesenchymal stem cells (MSCs) prevent the onset of bronchopulmonary dysplasia (BPD) in animal models, an effect that seems to be mediated by their secreted extracellular vesicles (EVs). The aim of this study was to compare the protective effects of intratracheally (IT) administered MSCs versus MSC-EVs in a hyperoxia-induced rat model of BPD. At birth, rats were distributed as follows: animals raised in ambient air for 2 wk ( n = 10), and animals exposed to 60% oxygen for 2 wk and treated with IT-administered physiological solution ( n = 10), MSCs ( n = 10), or MSC-EVs ( n = 10) on postnatal days 3, 7, and 10. The sham-treated hyperoxia-exposed animals showed reductions in total surface area of alveolar air spaces, and total number of alveoli ( Nalv), and an increased mean alveolar volume (Valv). EVs prompted a significant increase in Nalv ( P < 0.01) and a significant decrease in Valv ( P < 0.05) compared with sham-treated animals, whereas MSCs only significantly improved Nalv ( P < 0.05). Small pulmonary vessels of the sham-treated hyperoxia-exposed rats also showed an increase in medial thickness, which only EVs succeeded in preventing significantly ( P < 0.05). In conclusion, both EVs and MSCs reduce hyperoxia-induced damage, with EVs obtaining better results in terms of alveolarization and lung vascularization parameters. This suggests that IT-administered EVs could be an effective approach to BPD treatment.


2020 ◽  
Vol 27 (1) ◽  
Author(s):  
Yu-Wen Wu ◽  
Cheng-Chain Huang ◽  
Chun Austin Changou ◽  
Long-Sheng Lu ◽  
Hadi Goubran ◽  
...  

2021 ◽  
pp. 113843
Author(s):  
Alice Grangier ◽  
Julien Branchu ◽  
Jeanne Volatron ◽  
Max Piffoux ◽  
Florence Gazeau ◽  
...  

Transfusion ◽  
2009 ◽  
Vol 49 (11) ◽  
pp. 2285-2295 ◽  
Author(s):  
Eun Jung Baek ◽  
Han-Soo Kim ◽  
Ju-Hye Kim ◽  
Nahn Ju Kim ◽  
Hyun Ok Kim

2019 ◽  
Vol 42 ◽  
Author(s):  
Joseph A. Tainter ◽  
Temis G. Taylor

Abstract We question Baumard's underlying assumption that humans have a propensity to innovate. Affordable transportation and energy underpinned the Industrial Revolution, making mass production/consumption possible. Although we cannot accept Baumard's thesis on the Industrial Revolution, it may help explain why complexity and innovation increase rapidly in the context of abundant energy.


Sign in / Sign up

Export Citation Format

Share Document